Society - - SOCIETY SAYS SO -

IN APRIL 2016, I had the most trau­matic ex­pe­ri­ence on dis­cov­er­ing that my mother had stage four can­cer. Doc­tors had given up. But I didn’t. I con­tin­ued try­ing to find the best treat­ment for my mother. And dur­ing my des­per­ate hunt to save my mother’s life, I stum­bled upon Im­munother­apy. Im­munother­apy is a new class of can­cer treat­ment that is prov­ing to be the rare so­lu­tion to this killer of a dis­ease. Sci­en­tists work­ing on im­munother­apy have ba­si­cally taken a di­verse route by trick­ing the body’s own de­fences into com­bat­ing the ri­val can­cer within. For cen­turies, this has been an as­pi­ra­tion of med­i­cal sci­en­tists, which has now gone on to be­come a re­al­ity. Im­munother­apy with ‘den­dritic cells’ is the most re­cent and ex­cit­ing in­no­va­tion with re­spect to can­cer treat­ments. It is a com­bi­na­tion ther­apy that helps body’s own de­fences fight can­cer cells. It is in­fus­ing a new ray of hope for can­cer pa­tients. Count­less re­search and treat­ment fa­cil­i­ties world­wide are in­creas­ingly turn­ing to­wards this den­dritic cell ther­apy. In fact, even mod­ern na­tions like USA have well ac­cepted and ap­proved of this treat­ment. I can very well un­der­stand the de­spair and fear of los­ing a loved one af­ter my mother’s di­ag­no­sis. But I was ex­tremely sat­is­fied and con­vinced with the suc­cess rate of im­munother­apy. It proved to be very help­ful as my mother ac­tu­ally got rid of 80 per­cent of her can­cer. Her mirac­u­lous treat­ment hap­pened in Ger­many at the Lab­o­ra­to­ries Dr Gansauge (LDG). This is the clinic and lab where den­dritic cells are cre­ated. I took my mother there and got her in­jected with the den­dritic cells cre­ated out of her own blood. A sin­gle jab is needed in this new edi­tion. Although the con­cept is not new in the coun­try, it re­mains for­eign to the pre­vail­ing sys­tem due to the lack of knowl­edge and fea­si­bil­ity, both from the doc­tor’s and the can­cer pa­tient’s end. Hence, to serve the can­cer pa­tients in In­dia, I thought of bring­ing this med­i­cal in­no­va­tion to the coun­try my­self. More­over, it was my per­sonal ex­pe­ri­ence that mo­ti­vated me to start LDG In­dia in 2017. I am try­ing my best to bring the lab and this tech­nol­ogy here in In­dia soon. Till then, our clinic is send­ing blood sam­ples of can­cer pa­tients to Ger­many for the cre­ation of den­dritic

cells, which we in­ject in pa­tients here. By col­lab­o­rat­ing with the glob­ally ac­claimed med­i­cal fa­cil­ity of Dr Frank Gansauge, the pa­tients don’t have to go to Ger­many any­more. Our clinic is the first to in­tro­duce this new ver­sion of im­munother­apy in In­dia. While there are other sim­i­lar fa­cil­i­ties avail­able in the coun­try, which give vac­ci­na­tion in six cy­cles, at LDG In­dia, we will con­duct the same treat­ment in only one cy­cle. Thereby slash­ing cost and mak­ing it af­ford­able. Although the treat­ment by den­dritic cells has been in In­dia for a while, Dr Frank Gan­suage’s ver­sion of a sin­gle shot is a great ad­vance­ment in the im­munother­apy preva­lent in the coun­try. In­stead of be­ing the first treat­ment for can­cer, im­munother­apy is of­ten used when con­ven­tional ther­a­pies fail. Many pa­tients have so far been cured un­der the su­per­vi­sion of the famed can­cer spe­cial­ists in the coun­try. Ex­cept blood can­cer, im­munother­apy has been found ef­fi­ca­cious in treat­ing a num­ber of can­cers in­clud­ing skin, lung, kid­ney, breast, pan­cre­atic, colon, ovar­ian and prostate can­cer. This ther­apy has been ap­proved in Ger­many and USA long ago and over 10 thou­sand pa­tients have al­ready ben­e­fit­ted from it. The fact of the mat­ter is that this im­munother­apy by den­dritic cells should be the first in line treat­ment for can­cer be­cause noth­ing fights can­cer bet­ter than the pa­tient’s own in­nate de­fences i.e. his im­mu­nity. The ones who have un­der­gone this treat­ment have got bet­ter re­sults with­out chemo and ra­di­a­tion. But due to lack of knowl­edge and faith, pa­tients do not go straight away for this treat­ment. It’s too bold and risky an op­tion for them. That’s the rea­son why we ad­vise them to take the shot while con­tin­u­ing with the con­ser­va­tive treat­ments. The ef­fect is soon pal­pa­ble. The ef­fi­cacy of chemo­ther­apy also in­creases with a con­sid­er­able re­duc­tion in its side ef­fects. The pa­tient’s qual­ity of life is en­hanced to a huge ex­tent. The out­come of this treat­ment is surely headed to­wards com­plete re­mis­sion. This new ver­sion of im­munother­apy by den­dritic cells is al­ready prov­ing to be a game changer in can­cer treat­ments in In­dia and abroad.


It either trains the im­mune sys­tem to recog­nise the can­cer cells and de­stroys it, or it stim­u­lates the im­mune sys­tem to de­stroy the tu­mour cells by us­ing an­ti­bod­ies. There are sev­eral types of im­munother­a­pies. Pas­sive im­munother­a­pies (mon­o­clonal an­ti­bod­ies) The dif­fer­ent types of im­munother­a­pies are based on the work­ing prin­ci­ple of the hu­man im­mune sys­tem, which pro­duce an­ti­bod­ies when the body is in­fected by ex­ter­nal bod­ies like bac­te­ria, fungi etc. These types of an­ti­bod­ies are pre­pared ar­ti­fi­cially and are in­serted in the body in­tra­venously (through the veins). They work either by tar­get­ing spe­cific harm­ful pro­teins on the sur­face of can­cer cells, which are some­times de­serted by the im­mune sys­tem. Thereby help­ing the im­mune sys­tem recog­nise and de­stroy the can­cer cells, or help­ing in block­ing the can­cer growth fac­tor re­cep­tors (re­cep­tors that help in the growth of the cells). Also, mon­o­clonal an­ti­bod­ies, which carry ra­dioac­tive par­ti­cles, help di­ag­nose cer­tain types of can­cers like col­orec­tal, ovar­ian and prostate can­cer, with the help of spe­cial cam­eras. Some an­ti­bod­ies carry can­cer drugs di­rectly to can­cer cells and de­stroy them by latch­ing on to them. Non-spe­cific im­munother­a­pies These are usu­ally given in cho­rus with other tra­di­tional treat­ments like chemo­ther­apy. It is done either by us­ing lab­o­ra­tory pre­pared in­ter­fer­ons which slows down the growth of can­cer cells, or by us­ing in­ter­leukins, which de­stroy the can­cer cells. Ac­tive spe­cific im­munother­a­pies This par­tic­u­lar type of im­munother­apy in­volves spe­cific tu­mour anti­gens, which are in­fused us­ing can­cer vac­cines. Either sin­gle or two or more of the above types of im­munother­a­pies are used to­gether de­pend­ing on the need.


High­est suc­cess rates with no side ef­fects like hair loss, in­fec­tions, pain, vom­it­ing, nau­sea, di­ar­rhoea, weight loss, etc. Nor­mal cells are not af­fected or de­stroyed dur­ing the treat­ment. No dam­age to the taste buds. Avoids con­di­tions like O ste or ad io necro­sis( bone death) Treat­ment avail­able for all four stages of dif­fer­ent types of can­cer in­clud­ing pan­cre­atic can­cer, lung can­cer, melanoma, etc. Cheaper and af­ford­able. Can­cer is a lethal dis­ease that is swal­low­ing In­dia silently. Even those types of can­cer which were once known to be rare, are no longer rare. With this fa­tal dis­ease on a rise, it is tak­ing lives of many with each pass­ing day. As per the re­ports, in In­dia, ap­prox­i­mately 4.5 lakh peo­ple are liv­ing with the dis­ease, and there are more than seven lakh new cases be­ing reg­is­tered yearly, out of which 5,56,400 deaths are known to be can­cer-re­lated. It is also es­ti­mated that 71 per­cent of all can­cer-re­lated deaths are hap­pen­ing in the age group of 30 to 69 years. Con­sid­er­ing the im­pact and pro­gres­sion of can­cer, there has been no solid treat­ment to bat­tle this deathly dis­ease. But there fi­nally seems to be some light at the end of this dark and dread­ful tun­nel in the form of im­munother­apy.

Can­cer Cells

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.